ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/09/2019
Voltar para busca
Dado oficial do USPTO
ACCRETAMAB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ACCRETAMAB
ST13
US500000077178675Classe
5, 40, 42
Pedido
77178675
Registro
3653037
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
04/09/2019
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42
Data de depósito
11/05/2007
Data de registro
14/07/2009
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/04/2019
Última transação
10/04/2019
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
TOKYO, JP
Examinador
FAHRENKOPF, PAUL
Unidade examinadora
L10
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
KYOWA KIRIN CO., LTD.
KYOWA HAKKO KIRIN CO., LTD.
KYOWA HAKKO KOGYO CO., LTD.
Representantes
Kaushal R. Odedra ODEDRA LAW OFFICE, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Host cells for medical or clinical use; cells that manufacture antibodiesfragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodiesfragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticalscentral nervous system depressantspreparations for ophthalmic useanti-histaminicscardiotonicsarrhythmia treating agentsdiureticshypotensorsprophylactic for the treatment of asthmaantitussives and expectorantsstomachics and digestivesantacidshormonespituitary hormones for the treatment of infertilitythyroid hormones for the treatment of hyperthyroidismanabolic hormones for the treatment of aplastic anemia and osteoporosiscorticosteroids for treatment of hypopituitarismcongenital adrenal hyperplasiarheumatoid arthritisrheumatic fevercrohn's diseasechronic active hepatitisestrogen and progesterone used as combined oral contraceptivesurinary antisepticsanalgesicsanti-itching agentscataplasms for the treatment of bruiseslumbago and stiff shoulderpharmaceutical preparations used to treat hair disordersvitamin preparationsfood enriching agents for treating vitamin deficienciesanti-coagulantsenzyme preparations for control of malabsorption and diarrheaanti-cancer preparationsanti-sarcoma preparationsantibiotics and their preparations for the treatment of infectious diseasesantituberculotic agentsinfluenza vaccinesdiphtheria vaccinestetanus vaccinesgas gangrene vaccinesJapanese encephalitis vaccinesin vitro tetrodotoxines for medical useantiprotozoals for the treatment of trichomoniasis and dermatophytosisanthelmintics for the treatment of threadworm and toxoplasmaosisnaturally occurring drugs for treating peptic ulcerscharred drugs for treating peptic ulcersmoxa for treating peptic ulcersveterinary drugs for the treatment of distemper in dogsdistomatosis in dogscoccidian in chickensdysentery in pigsgermination controllers and plant rearing agentsherbicidesfungicidesinsecticidesbactericides and rodenticides for domestic and or agricultural useantisepticsdrugs for arteriosclerosisoncostatic drugs for the treatment for cancermultienzyme digestants for in vivo useantifungal antibiotics for treating trichomoniasis and dermatophytosisanti parkinsonism drugsminor tranquilizersanti anxiety agentsmedicinal preparations for the treatment of the central nervous systemthe respiratory tract and the cardiovascular systemanti-bacterial preparationsmonolithic preparationsmedicinal preparations for the treatment of peptic ulcersanti-inflammatory preparationsanalgesic preparationscephalosporincocarboxylase preparationsglutathione preparationspreparations for improving the metabolism and the peripheral circulationplasma substitutes and extracorporeal circulation flow improvement preparationsdiuretic and anti-hypertensive preparationsin vitro diagnostic reagents for medical usein vitro extra corporeal diagnostic reagents for medical usein vitro x-ray contrast agents for medical usein vitro diagnostic mediapharmaceutical preparations for the treatment of insomnia and other sleep related diseases
Classe 40
Contract manufacturing service in the field of antibodiesfragments of antibodiesderivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodiesfragments of antibodiesderivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodiesfragments of antibodiesderivatives of antibodies; contract manufacturing service in the field of host cells; contract extractingrefiningsynthesizingmanufacturing and preparing pharmaceuticalsagricultural chemicalschemicals; providing information in the field of manufacturing technology in the field of antibodiesfragments of antibodiesderivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodiesfragments of antibodiesderivatives of antibodies; providing information in the field of manufacturing technology in the field of cells that manufacture antibodiesfragments of antibodiesderivatives of antibodies; technical consultation in the field of manufacturing technology in the field of cells that manufacture antibodiesfragments of antibodiesderivatives of antibodies; providing information in the field of manufacturing technology in the field of transfected cells that manufacture antibodiesfragments of antibodiesderivatives of antibodies; technical consultation in the field of manufacturing technology in the field of transfected cells that manufacture antibodiesfragments of antibodiesderivatives of antibodies; providing information in the field of manufacturing technology in the field of host cells; technical consultation in the field of manufacturing technology in the field of host cells; providing technical information in the field of extractingrefiningsynthesizingmanufacturing and preparing pharmaceuticalsagricultural chemicalschemicals technical consultation in the field of extractingrefiningsynthesizingmanufacturing and preparing pharmaceuticalsagricultural chemicalschemicals
Classe 42
Development of new products for others in the field of antibodiesfragments of antibodiesderivatives of antibodiescells that manufacture antibodiesfragments of antibodiesderivatives of antibodiestransfected cells that manufacture antibodiesfragments of antibodiesderivatives of antibodieshost cells; providing technical information in the field of development of new products in the field of antibodiesfragments of antibodiesderivatives of antibodiescells that manufacture antibodiesfragments of antibodiesderivatives of antibodiestransfected cells that manufacture antibodiesfragments of antibodiesderivatives of antibodieshost cells; technical consultation in the field of development of new products in the field of antibodiesfragments of antibodiesderivatives of antibodiescells that manufacture antibodiesfragments of antibodiesderivatives of antibodiestransfected cells that manufacture antibodiesfragments of antibodiesderivatives of antibodieshost cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
10/04/2019
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
10/04/2019
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
10/04/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
08/04/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
14/07/2018
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
05/08/2015
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
05/08/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/08/2015
ES8R
TEAS SECTION 8 RECEIVED
01/07/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
14/07/2009
PUBO
PUBLISHED FOR OPPOSITION
28/04/2009
NPUB
NOTICE OF PUBLICATION
08/04/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
23/03/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/03/2009
ACEC
AMENDMENT FROM APPLICANT ENTERED
24/02/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/02/2009
PAPER RECEIVED
23/02/2009
CNSI
INQUIRY AS TO SUSPENSION MAILED
10/02/2009
CNSI
SUSPENSION INQUIRY WRITTEN
09/02/2009
ACEC
AMENDMENT FROM APPLICANT ENTERED
09/02/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/02/2009
PAPER RECEIVED
06/02/2009
CNSI
INQUIRY AS TO SUSPENSION MAILED
12/01/2009
CNSI
SUSPENSION INQUIRY WRITTEN
11/01/2009
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
11/12/2008
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
19/11/2008
CNSL
LETTER OF SUSPENSION MAILED
11/06/2008
CNSL
SUSPENSION LETTER WRITTEN
11/06/2008
ACEC
AMENDMENT FROM APPLICANT ENTERED
10/06/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/06/2008
PAPER RECEIVED
09/06/2008
CNSI
INQUIRY AS TO SUSPENSION MAILED
26/03/2008
CNSI
SUSPENSION INQUIRY WRITTEN
25/03/2008
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
24/02/2008
ALIE
ASSIGNED TO LIE
24/02/2008
CNSL
LETTER OF SUSPENSION MAILED
24/08/2007
CNSL
SUSPENSION LETTER WRITTEN
24/08/2007
DOCK
ASSIGNED TO EXAMINER
24/08/2007
NWAP
NEW APPLICATION ENTERED
16/05/2007
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ACCRETAMAB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.